CytoPherx Acquires Immunocept, Changes Name and Expands its Blood Filtration Platform Capabilities

July 12, 2018

Posted July 12, 2018 - Denver, CO

W.G. Nielsen & Co., a leading investment banking firm headquartered in Denver, announced today that it acted as financial advisor to CytoPherx in the acquisition of Immunocept.

Ann Arbor, MI- CytoPherx has completed the acquisition of Immunocept Medical Products, an emerging blood filtration company in Denver, CO which recently received FDA-Clearance to market its CLR 2.0 blood filter for use in patients with acute kidney injury, pulmonary edema and/or congestive heart failure.

About CytoPherx

The acquisition further strengthens the CytoPherx technology, known as the Selective Cytopheric Device (SCD), developed to treat very ill patients with acute kidney injury and multiple organ failures. The acquisition will ensure a synergistic approach to branding, manufacturing and customer call points. Both the Immunocept and CytoPherx devices are designed to fit onto standard, hospital ICU- based CRRT equipment, either independently or together, for improved patient benefit. The same contract manufacturer will now be used to build these devices, greatly improving efficiencies and lowering costs through volume manufacturing. Coming together strengthens IP protection with the combined patent portfolios (combined 62 issued and pending US, OUS patents) covering nearly everything that can be done with hollow fiber membranes in the acute inflammation, AKI and multi-organ failure therapeutic space. In addition, both products will be deployed in the hospital ICUs (pediatric and adult) by the same physicians for the same patients.
According to Charles J. Fisher Jr., MD and CytoPherx CEO, “We’re excited that this merger enables the immediate launch of the FDA-Cleared CLR 2.0 filter, creating revenues and early brand recognition for the family of products created by both companies to solve several real-world problems.”

The newly merged company, based in San Diego, will rebrand itself “SeaStar Medical”, paying tribute to a unique local creature that possesses regenerative, anti-inflammatory and cancer tumor- killing properties, creating a focused path forward for both short and long-term strategic developmental success.​

About W.G. Nielsen & Co.

W.G. Nielsen & Co. is one of the Rocky Mountain region’s premier FINRA-registered investment banking firms, specializing in mergers and acquisitions and innovative capital solutions. Founded in 1996, Denver-based W.G. Nielsen & Co. is the oldest independently owned investment banking firm in the region. The firm differentiates itself with a staff of senior investment bankers who have broad experience and important relationships in their areas of expertise. The firm’s bankers have collectively closed hundreds of transactions throughout the United States and internationally.

For more information about this transaction, please contact Ron Barber at 303.830.1515, or visit

<< Back to Blog